NASDAQ: TNYATenaya Therapeutics Inc Stock
$0.48+0.00 (+0%)
Updated Apr 29, 2025
TNYA Price
$0.48
Fair Value Price
-$0.11
Market Cap
$42.30M
52 Week Low
$0.39
52 Week High
$4.96
P/E
-0.37x
P/B
0.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$111.13M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.29
Operating Cash Flow
-$91M
Beta
1.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TNYA Overview
Tenaya Therapeutics Incorporated is a biotechnology company that develops heart diseases therapies in the U.S. It uses cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic Hypertrophic Cardiomyopathy, and TN-301, a small molecule inhibitor of Histone Deacetylase 6 (HDAC6i) for use in heart gFailure with preserved ejection fraction (HFpEF), as well as genetic Dilated Cardiomyopathy (gDCM). The company was incorporated in 2016 and is headquartered in San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TNYA's potential to beat the market
- TNYA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TNYA
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important TNYA news, forecast changes, insider trades & much more!
TNYA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TNYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TNYA ($0.48) is overvalued by 541.24% relative to our estimate of its Fair Value price of -$0.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TNYA ($0.48) is not significantly undervalued (541.24%) relative to our estimate of its Fair Value price of -$0.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TNYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TNYA due diligence checks available for Premium users.
Valuation
TNYA fair value
Fair Value of TNYA stock based on Discounted Cash Flow (DCF)
Price
$0.48
Fair Value
-$0.11
Undervalued by
538.50%
TNYA ($0.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TNYA ($0.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TNYA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TNYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.37x
Industry
-158.75x
Market
29.19x
TNYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.37x
TNYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TNYA's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.8M
Profit Margin
0%
TNYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$119.9M
Liabilities
$27.1M
Debt to equity
0.29
TNYA's short-term assets ($67.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNYA's short-term assets ($67.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNYA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TNYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.4M
Investing
$14.1M
Financing
$377.0k
TNYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TNYA vs Biotech Stocks
Tenaya Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.